An exploratory study on genomic profiling predicting chemotherapy resistance for advanced gastric cancer - TROX Study-A1

Kyushu Study group of Clinical Cancer0 sites120 target enrollmentMay 28, 2019

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Kyushu Study group of Clinical Cancer
Enrollment: 120
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

May 28, 2019

End Date

March 31, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Kyushu Study group of Clinical Cancer

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\)A patient who has received a transfusion, blood product, or hematopoietic growth factor such as G\-CSF up to 14 days prior to enrollment 2\)The patient has severe drug hypersensitivity 3\)The patient has peripheral neuropathy affecting the sensory nerves 4\)The patient has an active infection 5\)The patient has poorly controlled hypertension 6\)The patient has poorly controlled diabetes 7\)If a 12\-lead ECG reveals marked ECG abnormalities up to 14 days prior to enrollment or the patient has heart disease that may pose a problem 8\)The patient has severe pulmonary disease 9\)The patient has a psychiatric disorder that may pose a problem or a history of central nervous system dysfunction 10\)The patient has active gastrointestinal tract bleeding requiring repeated transfusions 11\)The patient is receiving phenytoin, warfarin potassium, or flucytosine 12\)The patient has moderate or more severe fluid accumulation in body cavities, such as pleural effusions and ascites, that continually requires treatment such as drainage 13\)The patient has brain metastasis or clinical features suggesting brain metastasis 14\)The patient has extensive bone metastasis 15\)The patient has watery diarrhea 16\)The patient has active multiple cancers 17\)The patient has a history of receiving platinum\-based antineoplastic agents 18\)A woman who is pregnant, nursing, or possibly pregnant or a man who is trying to conceive with a partner 19\)The patient tests positive for HBsAg or antibodies to HCV 20\)A patient who is deemed to need antiviral therapy for HBV\-related hepatitis 21\)A lead investigator or the patient's primary physician otherwise deems that participation in this trial is not appropriate for the patient